ストックスクリーナーアプリを入手
6.44
2.39%
0.16
前日終値:
$6.28
開ける：
$6.28
24時間の取引高:
305.83K
Relative Volume:
0.39
時価総額：
$229.75M
収益：
-
当期純損益:
$-144.01M
株価収益率:
-1.9398
EPS:
-3.32
ネットキャッシュフロー:
$-113.02M
1週間 パフォーマンス:
-9.56%
1か月 パフォーマンス:
-42.79%
6か月 パフォーマンス:
-44.47%
1年 パフォーマンス:
-35.31%
1日の値動き範囲:
$6.0919
$6.50
1週間の範囲:
$6.04
$7.11
52週間の値動き範囲:
$3.61
$22.74
Biomea Fusion Inc Stock (BMEA) Company Profile
BMEA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| BMEA | 6.43 | 229.75M | 0 | -144.01M | -113.02M | -3.32 |
| VRTX | 449.95 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.89 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.92 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 245.88 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.33 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-10-09 | 開始されました | Edward Jones | Buy |
| 2024-09-27 | アップグレード | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | アップグレード | Truist | Hold → Buy |
| 2024-08-29 | 開始されました | CapitalOne | Overweight |
| 2024-06-11 | ダウングレード | Truist | Buy → Hold |
| 2024-06-07 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-04-02 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-02-06 | 開始されました | Truist | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-06-26 | ダウングレード | Jefferies | Buy → Hold |
| 2023-05-12 | 開始されました | Barclays | Overweight |
| 2023-03-29 | 繰り返されました | Oppenheimer | Outperform |
| 2023-03-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2023-02-24 | 開始されました | Citigroup | Buy |
| 2022-06-02 | 再開されました | H.C. Wainwright | Buy |
| 2022-01-12 | 開始されました | H.C. Wainwright | Buy |
| 2021-12-17 | 開始されました | Oppenheimer | Outperform |
| 2021-05-11 | 開始されました | JP Morgan | Overweight |
| 2021-05-11 | 開始されました | Jefferies | Buy |
| 2021-05-11 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Biomea Fusion Inc (BMEA) 最新ニュース
HC Wainwright Reiterates Buy Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Late-Breaker Oral Presentation Showing New Analysis from - GlobeNewswire
Biomea Fusion's Diabetes Drug Shows 1.23% HbA1c Drop in Key Patient Group | BMEA Stock News - StockTitan
(BMEA) Investment Report - Stock Traders Daily
We're A Little Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate - Yahoo Finance
How To Trade (BMEA) - Stock Traders Daily
Biomea Fusion, Inc. Reveals Preclinical Data on Icovamenib and BMF-650 in Recent SEC Filing - Defense World
Biomea Fusion's SWOT analysis: clinical hold clouds diabetes drug stock outlook - Investing.com India
Biomea Fusion FY2024 EPS Estimate Raised by HC Wainwright - Defense World
HC Wainwright Forecasts Increased Earnings for Biomea Fusion - MarketBeat
Biomea Fusion (NASDAQ:BMEA) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World
Biomea Fusion’s (BMEA) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
BMEABiomea Fusion, Inc. Latest Stock News & Market Updates - StockTitan
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Biomea Fusion stock PT raised by Piper Sandler, citing pipeline potential - Investing.com Australia
HC Wainwright Reiterates "Buy" Rating for Biomea Fusion (NASDAQ:BMEA) - MarketBeat
Biomea Fusion Unveils Promising Diabetes Treatment Innovations - TipRanks
Biomea Fusion Reports Q3 2024 Financial Results - MSN
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate - GlobeNewswire
Barclays Forecasts Strong Price Appreciation for Biomea Fusion (NASDAQ:BMEA) Stock - MarketBeat
Biomea Awaits 2 Data Readouts Of Diabetes StudiesCan The Stock Get Its Mojo Back? - RTTNews
Biomea Fusion (NASDAQ:BMEA) Announces Earnings Results - MarketBeat
Biomea Fusion price target raised to $11 from $9 at Barclays - TipRanks
Biomea Fusion reports Q3 EPS (91c), consensus (95c) - TipRanks
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights - The Manila Times
Biomea Fusion options imply 6.1% move in share price post-earnings - TipRanks
Biomea Fusion, Inc. (NASDAQ:BMEA) Given Average Rating of "Buy" by Brokerages - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Rating of “Buy” from Brokerages - Defense World
(BMEA) Technical Data - Stock Traders Daily
Biomea Fusion shares maintain Buy rating from H.C. Wainwright By Investing.com - Investing.com Australia
Biomea Fusion's (BMEA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Biomea Fusion shares maintain Buy rating from H.C. Wainwright - Investing.com
Exchange Traded Concepts LLC Acquires 8,079 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Biomea Fusion's icovamenib gets global and US naming approval - Investing.com India
Biomea Fusion's icovamenib gets global and US naming approval By Investing.com - Investing.com South Africa
Biomea Fusion announces approval of ‘icovamenib’ as INN for BMF-219 - TipRanks
Biomea Fusion Announces Approval of 'icovamenib” as International Nonproprietary Name for BMF-219 - The Manila Times
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219 - GlobeNewswire
Biomea Fusion (NASDAQ:BMEA) & Acrivon Therapeutics (NASDAQ:ACRV) Financial Survey - Defense World
(BMEA) Investment Analysis and Advice - Stock Traders Daily
Griffin Asset Management Inc. Purchases 57,180 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - MarketBeat
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-21 - The Manila Times
Marshall Wace LLP Sells 3,900 Shares of Biomea Fusion, Inc. (NASDAQ:BMEA) - Defense World
Squarepoint Ops LLC Takes Position in Biomea Fusion, Inc. (NASDAQ:BMEA) - MarketBeat
Investigation Launched into Biomea Fusion Securities - Bit Perfect Solutions
Biomea Fusion Inc (BMEA) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):